1. Thailand Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Mega Lifesciences Public Company Limited

Mega Lifesciences Public Company Limited

MEGA-R.BK
Mega Lifesciences Public Company LimitedTH flagStock Exchange of Thailand
38.00
THB
+0.25
- -
33.13BMarket Cap

Total Valuation

Mega Lifesciences Public Company Limited carries a market capitalization of 33.13B, placing it among publicly traded companies globally. Its enterprise value stands at 25.63B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap33.13B
Enterprise Value25.63B

Share Statistics

Mega Lifesciences Public Company Limited currently has 871.87M shares outstanding.

Shares Outstanding871.87M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Mega Lifesciences Public Company Limited trades at a trailing price-to-earnings ratio of 14.32. The price-to-sales ratio is 2.06, and the price-to-book ratio stands at 3.19.

PE Ratio14.32
PS Ratio2.06
PB Ratio3.19
P/TBV Ratio3.22
P/FCF Ratio8.34
P/OCF Ratio9.68

Enterprise Valuation

On an enterprise value basis, Mega Lifesciences Public Company Limited trades at an EV/EBITDA multiple of 7.75 and an EV/FCF ratio of 7.12. The EV/Sales ratio of 1.79 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 8.47 provides insight into valuation relative to core operating earnings.

EV / Sales1.79
EV / EBITDA7.75
EV / EBIT8.47
EV / FCF7.12

Financial Position

Mega Lifesciences Public Company Limited maintains a current ratio of 2.29, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.32, indicating elevated leverage, while an interest coverage ratio of 54.27 demonstrates strong ability to service its debt obligations.

Current Ratio2.29
Quick Ratio1.62
Debt / Equity6.32
Debt / EBITDA0.20
Interest Coverage54.27

Financial Efficiency

Mega Lifesciences Public Company Limited posts a return on equity of 23.06 and a return on invested capital of 20.91.

Return on Equity (ROE)23.06
Return on Assets (ROA)13.60
Return on Invested Capital (ROIC)20.91
Return on Capital Employed (ROCE)22.18
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.19

Taxes

Over the trailing twelve months, Mega Lifesciences Public Company Limited has paid 584.42M in income taxes, reflecting an effective tax rate of 22.04.

Income Tax584.42M
Effective Tax Rate22.04

Stock Price Statistics

Mega Lifesciences Public Company Limited's stock has gained approximately 39.44954% over the past 52 weeks. The 50-day moving average sits at 33.79, while the 200-day moving average is 32.22.

Beta (5Y)N/A
52-Week Price Change39.44954%
50-Day Moving Average33.79
200-Day Moving Average32.22
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Mega Lifesciences Public Company Limited generated 14.35B in revenue and converted that into 2.07B in net income, yielding earnings per share of 2.37. EBITDA reached 3.31B, while operating income came in at 3.03B.

Revenue14.35B
Gross Profit7.49B
Operating Income3.03B
Pretax Income2.65B
Net Income2.07B
EBITDA3.31B
EBIT3.03B
Earnings Per Share (EPS)2.37

Balance Sheet

Mega Lifesciences Public Company Limited holds 4.64B in cash and equivalents against 664.32M in total debt, resulting in a net debt position of -3.80B. Total book value stands at 9.28B, with working capital of 6.55B providing operational flexibility.

Cash & Cash Equivalents4.64B
Total Debt664.32M
Net Debt-3.80B
Equity (Book Value)9.28B
Book Value Per Share10.66
Working Capital6.55B

Cash Flow

Mega Lifesciences Public Company Limited produced 3.06B in operating cash flow over the past twelve months. After subtracting -492.90M in capital expenditures, free cash flow totaled 2.57B - equivalent to 2.95 per share.

Operating Cash Flow3.06B
Capital Expenditures-492.90M
Free Cash Flow2.57B
FCF Per Share2.95

Margins

Mega Lifesciences Public Company Limited operates with a gross margin of 52.23, reflecting its pricing power and cost economics. The operating margin of 21.10 and net profit margin of 14.40 provide insight into operational efficiency.

Gross Margin52.23
Operating Margin21.10
Pretax Margin18.48
Profit Margin14.40
EBITDA Margin23.04

Dividends & Yields

The company's payout ratio of 67.50 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share1.60
Dividend YieldN/A
Payout Ratio67.50
Shareholder Yield4.38
FCF Yield12.00

Scores

Mega Lifesciences Public Company Limited posts an Altman Z-Score of 6.25, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score6.25